#바이오젠 #알츠하이머 #치료제 #비용 #논란 #글로벌기업 #리스크 #단독이슈 #ESG #디스클로저
Biogen’s $ 56,000-a-year Alzheimer’s Drug Reignites US Debate Over Costs
Biogen’s decision to price its recently approved Alzheimer’s disease treatment at $ 56,000 a year has reignited the debate about the high cost of drugs in the US, the largest and most profitable healthcare market. of the world.
Shortly after gaining US approval Monday for the first new Alzheimer’s drug in nearly two decades, the Massachusetts-based biotech group announced a price that was well above even the highest analyst estimates. Evercore ISI was expecting a price of $ 10,000 a year, while UBS, at the upper end of the range, had predicted $ 24,000.
Advocates of drug prices harshly criticized Biogen for the price it assigned to the drug, called aducanumab, adding to years of criticism of the company for the high cost of its drugs for conditions including multiple sclerosis and spinal muscular atrophy.
자세한 내용은
Biogen's $ 56,000-a-year Alzheimer's Drug Reignites US Debate Over Costs - Insider Voice더 많은 다른 이슈의 동영상은
디스클로저 Disclosure Analytics
책임의 한계와 법적 고지
디스클로저(disclosure)는 세계뉴스 빅데이터분석시스템으로 이미 생산된 뉴스를 '있는 그대로'를 소개합니다. 즉, 언론사의 뉴스는 언론사가 독립적으로 작성 또는 제작한 정보이기 때문에 디스클로저에서 그 정보의 정확성, 신뢰성 또는 적법성은 원칙적으로 해당 정보를 작성하였거나 혹은 제작한 당사자가 담보하고 이에 따른 책임을 부담합니다.
